China Medical Device Unique Device Identification (UDI) Requirements: A Complete FAQ

The China Medical Device Unique Device Identification (UDI) requirement mandates that all medical devices marketed in China be assigned a unique identifier that is affixed to the device or its packaging and submitted to the national UDI database. As of June 2025, China’s UDI system has been implemented in three phases, covering over **95%** of all marketed medical device categories, including Class III (highest risk), Class II (medium risk), and select Class I (low risk) devices. This FAQ answers the most common questions from foreign executives navigating this mandatory compliance system.

1. What is the China UDI System and Why Does It Matter?

The China UDI system, officially named the 医疗器械唯一标识 (Unique Device Identification, UDI, yīliáo qìxiè wéiyī biāoshí), is a national framework managed by the 国家药品监督管理局 (National Medical Products Administration, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú). It is designed to track medical devices from production through distribution and use, enhancing patient safety and recall efficiency. The core principle is that every device unit or package must carry a unique identifier that is linked to a central database.

Why it matters for your business: Without UDI compliance, your device cannot be legally imported, sold, or distributed in China. Non-compliance can lead to customs detention, fines, and market access suspension. The system aligns with but is not identical to the U.S. FDA or EU MDR UDI systems, meaning you must integrate a China-specific UDI process into your global labeling strategy. The NMPA’s UDI database currently contains over 1.2 million active device records, with 300,000+ added in 2024 alone, reflecting the rapid expansion of the program.

2. What Are the Key Compliance Timelines and Device Categories?

China implemented UDI in three distinct phases. Understanding which phase applies to your product is critical to your compliance timeline.

If your device was already on the market before its phase date, you are expected to be fully compliant by the effective date. New devices seeking NMPA registration must present UDI data as part of the application. The NMPA publishes updated lists on its UDI Co-reference Platform (唯一标识码数据库, wéiyī biāoshí mǎ shùjùkù), which receives approximately 25,000 new registrations each month.

3. What Data Must Be Submitted and Where?

For each affected device, you must submit two mandatory data components to the NMPA’s UDI database:

• Device Identifier (DI): The static identifier assigned to a specific model or version (e.g., GS1 GTIN, HIBC, or ICCBBA). This is stored in the database and linked to the device’s product registration number.
• Production Identifier (PI): The dynamic information identifying the specific unit or lot (e.g., expiration date, lot number, serial number). This is not stored in the database but is required on the physical label.

The database also captures the following metadata for each UDI record:

• Device trade name and common name (English and Chinese)
• NMPA registration certificate number (e.g., 国械注准2025XXXXXX)
• Manufacturer name and address
• Packaging level (unit, case, pallet)
• Labeling language requirements (all labels must be in Chinese)

Submission is done via the NMPA’s online portal, which requires an authorized account linked to your China legal entity (usually your 外商独资企业 (Wholly Foreign-Owned Enterprise, WFOE, wàishāng dúzī qǐyè) or local distributor). The NMPA integrates with the 国家药品代码 (National Drug Code, NDC, guójiā yàopǐn dàimǎ) system to cross-reference medical UDI data.

4. How Does China UDI Differ from the U.S. FDA UDI System?

While the overall concept is similar, key differences exist that can trip up global firms:

• Data Submission: The FDA maintains a public database (AccessGUDID) that you submit to directly. China’s system requires submission through the NMPA’s dedicated UDI portal, which also cross-checks your product against your NMPA registration certificate. You cannot submit UDI data without an active registration number.
• Label Format: The FDA allows both AIDC (barcode) and HRI (human-readable) on labels, though AIDC is preferred. China requires both AIDC and HRI on every label. The AIDC must be GS1-128, GS1 DataMatrix, or GS1 QR Code. The HRI must include the full UDI string below the barcode.
• Data Fields: China requires additional fields such as the NMPA certificate number and the Chinese-language trade name. The FDA does not require these.
• Direct Marking: For reusable devices, China requires direct marking on the device itself (e.g., laser etching) for Class III products. The FDA only requires this for devices intended for multiple use and reprocessing.

For example, a U.S.-based ophthalmic device manufacturer that already complies with FDA UDI must add the Chinese-language trade name, the NMPA certificate number, and submit to the China portal—adding approximately 3–6 weeks to the labeling preparation timeline.

Decision Framework: Adapt Global vs. Create China-Specific UDI

If your global UDI system already uses GS1 GTINs and your labels are relatively simple (no Chinese characters, single market), choose to adapt your existing labels by adding Chinese HRI language, a GS1-128 barcode that conforms to NMPA standards, and submitting to the China database. This is the faster path but may require manual translation and barcode testing.

If your product line is complex (multiple models, packaging levels, and languages), choose to create a China-specific UDI system using the NMPA’s recommended GS1 DataMatrix format. This allows you to separate your China UDI records from your global ones, reducing cross-market confusion. The trade-off is higher upfront setup cost (approximately RMB 50,000–150,000 for a dedicated China UDI database integration) but lower long-term risk of labeling errors.

5. What Are the Common Pitfalls and Their Costs?

6. What Are the Costs of UDI Implementation for Foreign Companies?

Typical costs for a mid-sized foreign medical device company entering the Chinese market include:

• IT System Integration (UDI database connection, GTIN generation, submission portal access): RMB 80,000–200,000
• Label Design & Testing (barcode verification, Chinese HRI translation, artwork revision): RMB 30,000–60,000
• Legal & Compliance Consultation (NMPA registration support, UDI data validation): RMB 50,000–150,000
• Annual Database Maintenance Fee: RMB 5,000–15,000

Total first-year investment typically ranges from RMB 165,000 to RMB 425,000 (USD 23,000–59,000), depending on complexity. This is a fraction of the cost of non-compliance.

NEXT STEPS

1. Review your current product portfolio and map each device to its China UDI phase. For devices already on the market, prioritize Phase 1 and Phase 2 compliance audits. Read our guide: NMPA Medical Device Classification: Which Class Is Your Product?
2. Audit your existing label and barcode systems for China compatibility. Identify all gaps in data fields (Chinese language, NMPA number) and barcode format (GS1). See: China UDI Label Compliance Checklist
3. Engage a local compliance partner with proven NMPA UDI submission experience. Execution matters more than strategy. Contact us at: China Gateway 360 Executive Consulting

— China Gateway 360 —
Remote China market entry support, built around execution.